While the risks associated with COVID-19 generally have decreased over time due to prior exposure to the vaccines and the virus, some people remain at elevated risk, such as the elderly and immunocompromised. The updated COVID-19 vaccines and, in some cases, a new monoclonal antibody can provide increased protection for this group.
After the Food and Drug Administration pulled its authorization of two COVID-19 antibody drugs because the treatments are highly unlikely to work against the omicron variant, Gov. Ron DeSantis of Florida misleadingly claimed the decision had been made “without a shred of clinical data” to support it. There may not be data from patients, but lab studies strongly suggest the treatments will not help omicron-infected people.
At a rally in Arizona on Jan. 15, former President Donald Trump waded into the debate over state policies allowing health systems to consider race as a risk factor when prioritizing the allocation of limited supplies of some COVID-19 therapeutics. According to Trump, it translates to white people being denied life-saving medicines and vaccines.
Calling investigational COVID-19 antibody drugs “cures” in a video posted to Twitter, President Donald Trump incorrectly said the therapies had been authorized and that “hundreds of thousands of doses” were nearly ready.